Disease · MONDO_0020753
Orthocoronavirinae infectious disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Orthocoronavirinae infectious disease. Diseases, record MONDO_0020753. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020753
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Coronavinae infectious disease, Coronavirus Infections, coronavirus disease, coronavirus infectious disease
- Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LEXGENLEUCEL-T | CHEMBL2107847 | Cell | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HYDROXYCHLOROQUINE SULFATE | CHEMBL1690 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FAVIPIRAVIR | CHEMBL221722 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| OLOKIZUMAB | CHEMBL1743050 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OSELTAMIVIR | CHEMBL1229 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AZOXIMER BROMIDE | CHEMBL4650378 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets29
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IFNAR1 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| TLR7 | Toll-like receptor 7 | 2 | Toll-like receptor 7 antagonist | Phase 3 | https://conductscience.org/library/genes/51284 | Drugs and targets |
| TLR9 | Toll-like receptor 9 | 2 | Toll-like receptor 9 antagonist | Phase 3 | https://conductscience.org/library/genes/54106 | Drugs and targets |
| CSNK2A1 | Casein kinase II subunit alpha | 1 | Casein kinase II alpha inhibitor | Phase 2 | https://conductscience.org/library/genes/1457 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Unknown | https://conductscience.org/library/genes/3156 | Drugs and targets |
| IL6 | Interleukin-6 | 1 | Interleukin-6 inhibitor | Phase 3 | https://conductscience.org/library/genes/3569 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase 1 | 1 | Inosine-5'-monophosphate dehydrogenase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| NPC1L1 | NPC1-like intracellular cholesterol transporter 1 | 1 | Niemann-Pick C1-like protein 1 inhibitor | Unknown | https://conductscience.org/library/genes/29881 | Drugs and targets |
1 to 10 of 29
See all 29 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04400058 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | Phase 3 | 207 | 2024-01-18 | Covid-19 | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT04756128 | Impact of Colchicine and Low-dose Naltrexone on COVID-19 | Phase 2 | 142 | 2023-07-25 | Covid19 | COLCHICINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT04542226 | Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19 | 81 | 2020-12-03 | Infections, Coronavirus | AZOXIMER BROMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04605588 | A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 | Phase 2 | 7 | 2022-05-05 | SARS-CoV Infection, Covid19 | HYDROXYCHLOROQUINE SULFATE, NITAZOXANIDE, RIBAVIRIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04338698 | Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT | Phase 3 | 550 | COVID 19 | AZITHROMYCIN, HYDROXYCHLOROQUINE SULFATE, OSELTAMIVIR | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT04381377 | Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19 | Phase 2/3 | 394 | Infections, Coronavirus | AZOXIMER BROMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04347031 | A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19 | Phase 2/3 | 320 | Pneumonia, Viral, Respiratory Failure | HYDROXYCHLOROQUINE, MEFLOQUINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05187793 | Study of Efficacy of Different Treatment Regimens of Olokizumab | Phase 3 | 198 | COVID-19 | OLOKIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04501783 | Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 | Phase 3 | 168 | COVID-19 | FAVIPIRAVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT04331054 | Protective Role of Inhaled Steroids for Covid-19 Infection | Phase 3 | 146 | Covid-19 Infection, Hospitalization in Respiratory Disease Department | BUDESONIDE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Octagam 10% vs Placebo: Number of Subjects With Severe Disease Progression | 15 of 105 | 12 of 102 | 207 | NCT04400058 | Trial comparisons |
| Octagam 10% vs Placebo: Proportion of Subjects Reaching Stabilization or Improvement in Clinical Status at Day 7 | 89 of 105 | 82 of 102 | 207 | NCT04400058 | Trial comparisons |
| Octagam 10% vs Placebo: Cumulative Mortality Rate Through Day 33 | 12 of 105 | 6 of 102 | 207 | NCT04400058 | Trial comparisons |
| Octagam 10% vs Placebo: deaths from any cause | 13 of 105 | 6 of 102 | 207 | NCT04400058 | Trial comparisons |
| Octagam 10% vs Placebo: Number of Subjects Reaching Stabilization or Improvement In Clinical Status at Day 14 | 86 of 105 | 83 of 102 | 207 | NCT04400058 | Trial comparisons |
| Octagam 10% vs Placebo: serious adverse events | 15 of 105 | 12 of 100 | 205 | NCT04400058 | Trial comparisons |
| Active Study Drug vs Placebo: deaths from any cause | 0 of 1 | 0 of 5 | 6 | NCT04605588 | Trial comparisons |
| Active Study Drug vs Placebo: serious adverse events | 0 of 1 | 0 of 5 | 6 | NCT04605588 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020753
GET https://conductscience.org/api/diseases/v1/MONDO_0020753/drugs?page=2